Larger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.
Melanie Senior
Advertisement
Melanie Senior, author, Evaluate’s Orphan Drug Report 2022
Articles by Melanie Senior
Advertisement
Latest Updated Articles
Orphan Drugs: From Niche to MainstreamJune 15th 2022
Advertisement
Advertisement
Trending on PharmExec
1
Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
2
Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials
3
Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq
4
Beyond Traditional Strategy Consulting Firms: Why MBA Students Should Consider Turnaround, Restructuring Consulting
5